PARSIPPANY, N.J., Aug.  07, 2026  (GLOBE NEWSWIRE) -- Embecta Corp. (&#34;embecta&#34;) (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies

EMBC

Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results

Embecta Reports Q3 FY2026 Results as It Expands Medical Supplies Focus

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>PARSIPPANY, N.J., Aug.  07, 2026  (GLOBE NEWSWIRE) -- Embecta Corp. (&amp;#34;embecta&amp;#34;) (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Embecta reported Q3 FY2026 results, aligning with its strategy to broaden beyond insulin delivery into medical supplies. The earnings press release and investor presentation, plus an 8:00 a.m. ET conference call, will reveal revenue mix, margin trends, and guidance likely driving EMBC stock in the near term.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Embecta reports Q3 FY2026 results. Earnings press release issued Aug 7, 2026.</li><li>Conference call at 8:00 a.m. ET today; live webcast and IR site links.</li><li>Company aims to broaden insulin delivery into broad medical supplies; 2,000 employees.</li><li>Parsippany, NJ. IR materials online; earnings presentation available.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>embecta (EMBC)</strong>: Directly reports Q3 FY2026 results; earnings press release and investor presentation; conference call at 8:00 a.m. ET; near-term price impact depends on disclosed metrics and guidance.</li></ul>
  </section>

  <section data-block="category">
    <h3>Earnings</h3>
    <p>Category: Earnings. This article centers on quarterly results and an investor call, signaling near-term fundamental catalysts. The stock’s reaction will hinge on disclosed metrics and any forward guidance tied to Embecta’s pivot toward a broader medical-supplies portfolio.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Q3 FY2026 earnings results and any guidance could trigger immediate EMBC price movement.</li><li>Aug 7, 2026 conference call and investor presentation to provide forward-looking metrics.</li><li>Strategic pivot to broader medical supplies may influence long-term valuation.</li><li>Market reaction hinges on actual numbers; this notice lacks detailed figures.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>EMBC trades on Nasdaq under the ticker EMBC.</li><li>Date of release and call: Aug 7, 2026 (Q3 FY2026).</li><li>Conference call scheduled for 8:00 a.m. ET.</li><li>Webcast replay available starting 11:00 a.m. ET on Aug 7, 2026 for one year.</li><li>Embecta employs about 2,000 people worldwide.</li><li>Headquartered in Parsippany, New Jersey.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral to modestly bullish into earnings; a solid beat or higher guidance could lift EMBC 1–4 weeks.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>PARSIPPANY, N.J., Aug.  07, 2026  (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/EMBC">EMBC</a>), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported third quarter fiscal 2026 financial results.</p>  <p align="justify">Visit the company’s Investor Relations website at <a href="https://www.globenewswire.com/Tracker?data=YoX0UBC5uPVu-DULKDt3Zj9UbQe2bMb1dXobjOpdCT5Z1zKNYRKmMCbElHtvAtzdNvu2DU7gUig_gNPQJ6p10q3xQh6BPK-Zek7WJSc_6SGkqH6GByMKT148IJEhIHhf" rel="nofollow" target="_blank">http://investors.embecta.com</a> to view the detailed third quarter fiscal 2026 <a href="https://www.globenewswire.com/Tracker?data=3vfu00m3qVcLjap5o0fH34ve3rD6jk6w1oNDEjATjoZbGzSozLV5VS6Rry_0uZLKJSfuWfoIQMdxqlvsEr-5frvb0Ofcn3tMfOStR1ClHLIQBBcEyv4gIov2aNnEmJVB9axcUpgjiUORVotyVv4mfZ466IOtX20j8dBd83w6hr0=" rel="nofollow" target="_blank"><strong>earnings press release</strong></a> and investor presentation.</p>  <p align="justify">The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, Aug 7, 2026, which is accessible <a href="https://www.globenewswire.com/Tracker?data=KFRbfB-MFbe8hYEkeUWjk_FZmlgeCUpusbABZsuAlNopovHNeuLn95OIFeoAZ_-y9vK-6DhLqg_VnA2ozry757tkb1p9y4DgLduRFJQ7hAQ=" rel="nofollow" target="_blank">here</a>, or access the teleconference <a href="https://www.globenewswire.com/Tracker?data=KFRbfB-MFbe8hYEkeUWjk1ZNb_6ibusAx_nEXe5N872Z19oYtAfMtPkXNy0UPxC4sIka_GhAhxYzLbYS7-G3qlyVkCcZK7rHbkVb6ULfzIFswF4cgfISrRXzRQzvaKxH1OFc9McA108-LEnZI6wRsXWmOVi1V5b0VwLA0fj5za8=" rel="nofollow" target="_blank">here</a>. The live webcast can also be accessed via the company’s website at <a href="https://www.globenewswire.com/Tracker?data=j-4hfTHKv5Osve8nAixhXUa0apHtm6Bz4h-kDNx5VfGOPNDWboo45sgVSS05CJ2qfJU8iVPZZQXWslapyRPFYZvNOH8i53K3HpjCa_Oa4AE=" rel="nofollow" target="_blank">investors.embecta.com</a>.</p>  <p align="justify">A webcast replay of the call will be available beginning at 11:00 a.m. ET on Aug 7, 2026, via the embecta investor relations website and archived on the website for one year.</p>  <p><strong>About embecta </strong></p>  <p align="justify">embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=Y6DzlwCgkutH6utVLcYNDBRcrjsoVJtPqdy0Ey264YU7waJeTqLfeDBIhmxl4Q6x9Z0ZcmA8JU2NedMK1ME853GDgZMOch-cgyL0gj7ZcHtmRvh-j4R4l7sqUJO4-E-9olE8-U_SiRd2EBWIohnikgxv9KBZJLiH9saLFZc2gy2Tr4I9MrxKtQi9pqwHSK3iJWnKYymPfyxLpSxH_zmne3zpw1m5Wju_IfRjqydJI6MChr2ibmK-3fjGltN8y129KBiZx_aSQfD0UYBfJFTw8eSZF7cwdaG3-Wm9Ge7kpSM6VI38BTU4f3kw24_uUM72Qmay239V_b-0_Nrt3AGQr3KAKUm60--XlFTsAWmsbLckXPMTVAybbctBQKKdkbNdd3EvRSNE5CKydawJQROa1a2Eh3MNSRP7hkRijIT67Ihg-bHx6Bl6aozDCMDNbmzOiwjy-UYH8GgdBcBjRzp4IA5kmi73WdlzMFuldesTEIFRKmmz2f1tZ_83BrvjknY8ngZvhV51TWYrlHBJqBaKzxE8LXaiksWakdU3qzDrezOrPk8p4FMNQhOw0mmGbz2-dv9Q3KHGq352SukO-_3NbTRyZRqNOi_ANbn4rB2hON3ULS0u6ge9AQhVS1L0DRTsXq7wELl3S26s-xO5zH671r3RzfrdZtUBn-16W3i9TyOVCRDHFgmISedV99NlodRWO7EP5FK5TYzjp9-I3Au9iETVOMSItMViC80svd7mxUs=" rel="nofollow" target="_blank">embecta.com</a> or follow our social channels on <a href="https://www.globenewswire.com/Tracker?data=y6dU3l1YzhiO5Fd6HlZTZ-ZLPhWJILH6F0ECFwJfvU_O_QdsLC-ifpZSh6KR5uVBYf40k6N8l0_VxHwYtKZSAbNbaHNzsLHwJR0dnOrqpUgtAvNpSfh5hdENU5RfYERRx80-d80y6ISI25BamUSQAvJFFELeIvI6C6JUUg9KjExlo9LaprmvmxDMrq19J5TWkTcPSDURtUJJEM5-hDGMrOv4BfebArafJOZzu00YieUpwsUy2mGmLsVN-wfuV9xypvTQceEZy_yF-DQqt1LkIJXojLxKORe_WHs-Yzn4DU4Pfn0d-xuwVyVIPhWLmFEwH6SrsMuByM2Bg6IRTZ5b5omY_FxAoGkmURHOS7awBZN5DXkceYYrhP4G28-n2SmdUV1nqIrYk8ih1WcuxIQUtAN85ql56ABLygyAnaiqZtjjDIj4w2osJl93Aubj7SBvYgW4mRVaL5-IHl5au1sTk-k68w6bKodQKTB6TSpXnfDddWs05LORFb_-3Bla_zJQkwyN4-UsRh8EEYX8TEcCLYsLx_PO2nUZAH6Jk-emtpLXWeha5VhOJr5wu2Zus7oubwxTlNKFUeCwOEaVGg2BUSZe78ctt4xqaZ4PQA8MO0a5E6f_0m5d-TQz327mqtZbU8oSM0kjtJy-EvWXlfSh3CAB8-j6ll-aN38jk6gErPmQBEKiEzQYSQvAEZRwwEwL3XPtpvnNGTMZ17H-Oda1nPSb8Q91B6wehuERnuVIHhp3A5-HUWjtdsdg5N1VbYrM2O4JxO-3ZbnjCvRemz6Vrw==" rel="nofollow" target="_blank">LinkedIn</a>, <a href="https://www.globenewswire.com/Tracker?data=x89bAcNWaI37uteeYn1YQ1H7EKw5XrHH2KRNjweAYvBNOwiy-qt5ocv4isMkUaTxhocRZnIN_fGB-tvkeadp5kWPBLdGGnCf5sRrqx3thR4F69o26jAmtTI-Hiy4i9pvmJE7OtPgL2H5KpGrCwfEdxlVwJ0f7-f56HYSL1dHUDDYIFLOT43F-AZrMVkLx31P4OJqa8X_L_BoFYj_X7471D7FhBIXL24xcxKvEcoKIAMyrhlU8PINzrOBwx7hmndVKLCA9vBiKA2ZTB9FKt12W2R94UvJartNCvwWVNIvYSafsjVjoO1WRF7SjXNLu9dHNnWQGowwbN6GhHdJnKucojLW9-jKhVnVwydudtFyBrH-NvpSPbp-huRaZfNkp6W5B67LejZHXXp07XA84z7-WrNESku1rUHMEGTqKwKd7ZCxSgfxKTPZSbDaFXZgZXjvyDLD1SCQP66lvlMzTPvlTHeHsRV-18QZ5zwJVtxxdoAgiYs9NLK7RrN7_M_ucN92pHt2YDpm25SF51LucLlfFF3vfUJNf8Sl4h4CU2GVC4pN26ASBoj0J8ku2piuHvR5byiivAGfAd6fQeTbVWhGZ2IEj4pejEr2yzv6lszIGcRqeVJU4aDcyEq85z4vN50k7TVgF-wSN43S5mQHurCoZpV5-oHL_9_ck2U722yLhuZ7sqoLp1ceRv02kTwJm_RmexaRrylL75bt0PMFcutcszWpeP3aH6VFxEDFebPqagj-yFbujG83J3eCk1N-amC4" rel="nofollow" target="_blank">Facebook</a>, and <a href="https://www.globenewswire.com/Tracker?data=B0sKNzBjmBoMcRf6W5epYV7idP_KNLFqjaq6TtbpMxwNXYBLIDBDuZaWl2g_gRFKN17nWUxmFGMnPMsR_z9QJ9T3ucoYwuWSWaVTFke35PzZKZZwu6hgLoa79W0zCOdv3-iluPIF-lpM0Ery3juEPqrwWVEkVTf3tbteLZzM8m_R-kB_mzwrpzv8RdYKUoU2V3bop0fgttLsl82ZUsvE0KAcnrAgDFIOH0asCcGaTF3lKGArZ1C3TeN9pG_S0RiUPOCHljscOm22tx0tgT0CAqaG3RhOf2EjX_-FebvOnsiFuM64AOLTnAKofkme4jiLsrFbCsDTfqOeAOF9MnC7BXfpvE6k0L_ZpKLrKNCF-WDj8WyOevlCWc1C2gsEIKrsDVvC3_TMlRxiHI4Nle9FtFimoOHbfcJ8EA2Ch34AHqcg_t_Jf5yPdpwfpJAdOuD0cH_ty0VkOOo6tXUx6pgXRDcjT70RghGKTPu7ibTFGQw9VngkGUMOa49CWJOsSYvpXqSOoZ7-MfZGOeJ4QJ19QKcwlEE5l7PanC-XG_tjfG-oOdxr5jooLZufqVuDwsXb2i56oTF1e3cPckqBk_f1SD7Z4MU5WOCZ_ZnJT_jTxeKrFOiYdtptEePooPucG740mO0jVwwX5hOsnSp-lhxxfaLAiNT36dMx6jZq1p7Ul8pI6mIEW8wvYrHEloTeXD73BWzUd3rmNYdx00on-o1MvcfhAlNhiLKIQX5VG5fy_cata-fnasb5uUA5lrC5cNMV" rel="nofollow" target="_blank">Instagram</a>.</p>  <p><strong>Contacts:</strong>    </p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:49.7857%;">Media</td><td style="width:49.7857%;">Investors</td></tr><tr><td style="width:49.7857%;">Christian Glazar</td><td style="width:49.7857%;">Pravesh Khandelwal</td></tr><tr><td style="width:49.7857%;">Sr. Director, Corporate Communications</td><td style="width:49.7857%;">VP, Head of Investor Relations</td></tr><tr><td style="width:49.7857%;">908-821-6922</td><td style="width:49.7857%;">551-264-6547</td></tr><tr><td style="width:49.7857%;"><a href="mailto:media.relations@embecta.com" rel="nofollow" target="_blank">Contact Media Relations</a></td><td style="width:49.7857%;"><a href="mailto:investor.relations@embecta.com" rel="nofollow" target="_blank">Contact IR</a></td></tr></table> <p><br></br></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgwNTUxMSM3NzY0MDMwIzIyNDQ1Njk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MTA2OWRiZWYtMGIwZC00N2FiLTg1MWYtOWUwZWIxM2VjNmQ5LTEyNTYxMjItMjAyNi0wOC0wNy1lbg==/tiny/Embecta-Corp-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/fa3e492e-f542-4291-a7e2-bdd2c3dff424"><img src="https://ml.globenewswire.com/media/fa3e492e-f542-4291-a7e2-bdd2c3dff424/small/embecta-logo-jpg.jpg" border="0" width="150" height="75" alt="Primary Logo"></img></a></p>

Embecta reported Q3 FY2026 results, aligning with its strategy to broaden beyond insulin delivery into medical supplies. The earnings press release and investor presentation, plus an 8:00 a.m. ET conference call, will reveal revenue mix, margin trends, and guidance likely driving EMBC stock in the near term.

News insight

Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results

AI summary

Sentiment rationale

Key facts

Earnings